Login to Your Account


HONG KONG –With a new deal with Ferring Holdings Ltd. to option its innovative microbiome-focused technology, Israel's Mybiotics Pharma Ltd. is looking to expand its market and develop new products. Its second option agreement with Ferring is based on validation of Mybiotics' microbiome-based therapeutic technology focused on women's health.

SHANGHAI – Two-year-old Engine Biosciences Pte Ltd., a startup with an artificial intelligence (AI) platform approach to drug discovery, recently received a $10 million endorsement from Chinese and U.S. investors.

LONDON – Convert Pharmaceuticals SA has raised €13.6 million (US$16.9 million) in a first funding round, to take a fresh attempt at developing a hypoxia-activated prodrug (HAP) for treating solid tumors.

More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: